Clarivate Webinar: New frontiers in diagnostics: opportunities and challenges post-pandemic

Webinar cover image - New frontier in diagnostics- opportunities and challenges post-pandemic. Image links to the webinar site. You can watch the video there.

  Immunexpress CEO Rollie Carlson participated in a webinar on medical diagnostics, hosted by Clarivate™. Other participants: MICHAEL WARD – Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate LISHAN AKLOG, M.D. – Chairman and Chief Executive Officer, Lucid Diagnostics MARK MCDONOUGH – Chief Executive Officer, ChromaCode ELLIOTT GREENSPAN – CIO and Co-Founder Igentify

Read More

Independent Studies Presented at ESCMID Global Demonstrate the Clinical Utility of SeptiCyte® RAPID in Patients Suspected of Sepsis, Including in Polytrauma Patients

Immunexpress - the signature diagnostics for sepsis

SeptiCyte® RAPID accurately differentiated between nosocomial infections and systemic inflammatory response syndrome in polytrauma ICU patients suspected of sepsis. SeptiScore® was elevated in ICU patients suspected of sepsis when a causative pathogen was identified. SEATTLE and BRISBANE, Australia, April 17, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis…

Read More

Accurate Identification of Sepsis using SeptiCyte® RAPID and Comparison with other Biomarkers Presented at Society of Critical Care Medicine Critical Care Congress 2024

Immunexpress - the signature diagnostics for sepsis

This press release was first published at PR Newswire SEATTLE and BRISBANE, Australia, Jan. 22, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced  that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for presentation on Sunday, January 21, during…

Read More

“Improving Outcomes For Patients With Sepsis” — Interview from Progress, Potential & Possibilities

Roland Carlson interview for Progress Potential Possibilities

“Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they’re committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying from whole blood specific molecular markers…

Read More

Data Presentation at Association for Molecular Pathology 2023 Validates Performance of SeptiCyte® RAPID in Immunocompromised Patients and Patients on Immunosuppressive Therapy

Immunexpress - the signature diagnostics for sepsis

SeptiCyte® RAPID may aid clinicians in determining early antibiotic administration and in bundle compliance for immunocompromised patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Nov. 17, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation validating the utility of SeptiCyte® RAPID…

Read More

Rollie Carlson on How Cross-Training and Extreme Ownership Help You Advance Your Career

Carlson - Mastering Medical Device podcast

Immunexpress CEO Rollie Carlson recently appeared on the Mastering Medical Device podcast. Rollie Calrson is the CEO of Immunexpress, a company that is pioneering technology that can rapidly detect sepsis. Rollie contributed to the success of Abbott Laboratories for 20 years, starting off in R&D, then transitioning to leadership positions in global businesses and start-up…

Read More

Immunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID®

Immunexpress.com

EDTA blood collection tubes are used routinely in clinical settings for hematology procedures around the world SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug…

Read More

SeptiCyte RAPID® By Immunexpress Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA)

Cision PR Newswire

The Cost of Sepsis in Australia report (2021) estimated that there are >90,000 sepsis cases in Australia each year and estimated direct and indirect costs of $700 million and $4 billion respectively SEATTLE and BRISBANE, Australia, Jan. 17, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis…

Read More

CHEST 2023 Poster Demonstrates the Utility of SeptiCyte® RAPID in Antibiotic Administration and Sepsis Bundle Compliance

This official press release was first published on PRNewswire SeptiCyte® RAPID may aid clinicians in making a determination on early antibiotic administration and in bundle compliance for patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Oct. 2, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected…

Read More

Immunexpress Announces Adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas

SEATTLE and BRISBANE, Australia, July 20, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for patients suspected of sepsis, announced today the adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas, a non-profit health system licensed for four hospitals in Pinehurst, Troy, Rockingham and Raeford, North Carolina. SeptiCyte RAPID will be available at FirstHealth as a tool in differentiating…

Read More